S60 New Technologies in Type 1 Diabetes

Program: Symposia
Clinical Session
Sunday, April 3, 2016: 4:45 PM-6:15 PM
BR East (BCEC)
Marie E. McDonnell, MD, Brigham and Women's Hospital, Boston, MA

Nothing to Disclose: MEM
4:45 PM
Chantal Mathieu, MD, PhD, Endocrinology, Catholic University Leuven (KU Leuven), Leuven, Belgium
CM: Ad Hoc Consultant, Astra Zeneca, Ad Hoc Consultant, Eli Lilly & Company, Ad Hoc Consultant, Jansen Pharmaceuticals, Ad Hoc Consultant, Merck & Co., Ad Hoc Consultant, Novartis Pharmaceuticals, Ad Hoc Consultant, Novo Nordisk, Ad Hoc Consultant, Roche Diagnostics.
5:15 PM
Larry A Fox, MD, Nemours Children's Health System, Jacksonville, FL
Nothing to Disclose: LAF
5:45 PM
Steven Jon Russell, MD, PhD, Diabetes Research Center, Massachusetts General Hospital, Boston, MA
SJR: Scientific Board Member, Tandem Diabetes Care, Ad Hoc Consultant, Sanofi, Speaker, Eli Lilly & Company, Principal Investigator, Eli Lilly & Company, Principal Investigator, Tandem Diabetes Care, Speaker, Dexcom, Speaker, Sanofi, Principal Investigator, Dexcom, Scientific Board Member, Companion Medical.
See more of: Symposia


The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire